Chemomab Therapeutics Ltd. (CMMB): Financials
Trailing 12 months ended June 30, 2023
Income statement, cash flow and balance sheet figures for Chemomab Therapeutics Ltd. (CMMB), read directly from the XBRL data the company files with the SEC. Net loss was $33.1M, or $0.15 per diluted share. Free cash flow was -$25.7M.
Against the current share price, CMMB trades at 18.7 times trailing earnings.
8 fiscal years of history are available, back to 2018.
Frequently asked questions
How much revenue does CMMB make?
Revenue for Chemomab Therapeutics Ltd. comes from the company's SEC XBRL filings. When the company reports a tagged revenue figure it appears on this page.
Is CMMB profitable?
Chemomab Therapeutics Ltd. was unprofitable over the trailing twelve months, with a net loss of $33.1M.
Where does this financial data come from?
Every figure on this page is read from the company's own SEC 10-Q and 10-K filings. Nothing is estimated by a third party. Quarterly figures a company does not file separately (most commonly the fourth quarter) are derived by subtracting the reported year-to-date quarters from the full fiscal year, and are labelled as derived.
What is the difference between quarterly, annual and TTM?
Quarterly shows each three-month fiscal period on its own. Annual shows the full fiscal year as filed in the 10-K. TTM (trailing twelve months) sums the last four reported quarters, which is the most current annualised view between 10-K filings.